Case Report

Malignant Diffuse-Type Tenosynovial Giant Cell Tumor in the Subcutaneous Tissue of the Midthigh: A Report of a Rare Tumor in an Unusual Location

Omar Salem,1 Khalid Kurdi,1 Amani Joudeh,2 Ahmad Al-Dhafiri,3 Zahra Alkhunaizi,2 and Emad Al Absi1

1Department of Orthopedics, King Fahad Specialist Hospital, Saudi Arabia
2Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Saudi Arabia
3Department of Medical Imaging, King Fahad Specialist Hospital, Saudi Arabia

Correspondence should be addressed to Omar Salem; osalemo@gmail.com

Received 9 April 2022; Accepted 29 July 2022; Published 19 September 2022

1. Introduction

Tenosynovial giant cell tumors (TS-GCT) are common soft tissue tumors that originates from synovium of joints, tendons, and bursae [1]. On extreme rare occasions, malignant transformation has been found. Malignant TS-GCT are mostly located in the periarticular soft tissue of the lower extremity. Only few cases are found to be remote from the articular area. In this article, we would like to share our experience with a 34-year-old female with subcutaneous malignant TS-GCT of the right midthigh. Presence of such lesions in such unusual location could be misleading and diagnostically challenging. We also would like to point common clinical, radiological, and histological features that was observed while reviewing the literature.

2. Case Presentation

Our case is a 34-year-old female who presented with a slowly growing painless mass in the right midthigh over a year. It was not painful and was not interfering with her activity. Clinical examination showed 5 × 4 cm mass in the lateral aspect of the midthigh. The mass was superficial to the underlying muscles and fascia. MRI showed a well-defined oval shaped soft tissue mass in the superficial subcutaneous tissue of the right proximal thigh (Figure 1). The lesion is measuring 3.5 × 4.4 × 3.8 cm. It was separated from the lateral and posterior compartment thigh muscles and fascia by a clear fat plane. The mass was homogenous T2 hyperintense as well as T1 signal intensity that is slightly higher than skeletal muscles. Postcontrast images show intense homogenous enhancement without necrosis. The mass was worrisome for soft tissue sarcoma so bedside tru-cut biopsy was done. Histological examination shows nested pseudovascular proliferation of histiocytes and synoviocytes showing abundant eosinophilic cytoplasm with some perinuclear hemosiderin. Scattered multinucleated osteoclast-like giant cells were seen. Our initial impression was benign diffused type tenosynovial giant cell tumor (Figure 2). Due to the aggressive behavior of such lesion, wide local excision was done with negative margins. Further histopathological analysis of the mass showed atypical cytological features, increasing cellularity and abundant eosinophilic cytoplasm in the histiocytoid cells which was
Figure 1: Continued.
consistent with a malignant process. The patient received post-operative adjuvant radiation therapy (PORT) 60Gy/30Fs followed by adjuvant chemotherapy a total of 6 cycles of doxorubicin/dacarbazine. The patient is 14 months after the surgery, and she is disease free.

3. Discussion

TS-GCT are a group of benign soft tissue tumors that originates from the synovium of the joints, tendons, and bursae [1]. They were first described by Jaffe et al. in 1941. They are divided into two types localized and diffuse based on their growth pattern. Each can present either intra-articular or extra-articular. Due to its high proliferative index, diffuse-type TS-GCT has the propensity to be more aggressive and may therefore lead to joint impairment [1, 2]. However, both have a high tendency of local recurrence, with metastases being extremely rare.

Due to the polymorphic nature of TS-GCT, it was initially thought that it represents reactive inflammatory changes of the synovium. Since it malignantly transforms, they were then considered to be neoplastic in nature [3]. The identification of genetic abnormalities including rearrangement of 1p11–13 and the CSF1 locus in these tumors further supported the neoplastic hypothesis [1, 2].

Malignant TS-GCT tumor is extremely rare. They are believed to represent for less than 0.1% of benign TS-GCT [4]. It was first described by Castens and Howell in 1979. They described malignant recurrence of a previously benign TS-GCT of the foot [3]. According to Enzinger and Weiss, malignant TS-GCT is defined by the presence of sarcoma within or at a site of previously excised benign TS-GCT. They classified them into primary (De novo) and secondary (metachronous), primary when both benign TS-GCT occur with a coexisting sarcomatous component on initial presentation, while secondary presents as a sarcomatous recurrence of a previous beginning giant cell tumor of the tendon sheath [5]. The sarcomatous component of malignant TS-GCT was found to present in different forms including GCT-like, fibrosarcoma-like, MFH-like, myxofibrosarcoma-like, and osteosarcoma-like. GCT-like pattern was found to be the most common form. Several other lesions were found to share histological features with malignant TS-GCT including, primary carcinoma, metastatic melanoma, primary myxoid chondrosarcoma, osteosarcoma, and malignant fibrous histiocytoma. This makes histological identification of malignant TS-GCT challenging [6].

Bertoni et al. identified common histological features that are found in both primary and secondary malignant TS-GCT, including (1) nodular and infiltrative growth pattern of the synovium and surrounding tissue; (2) large, plump, round, or oval cells with eosinophilic cytoplasm; (3) large nuclei with prominent nucleoli; (4) fewer benign giant cells and xanthomatous cells and inflammatory cells; (5) no maturation between the periphery and the center; and (6) extensive necrosis [6].

Because of the histological variability, the origin of the tumor was unclear. Recently, Al-Ibraheem et al. did extensive immunohistochemical and cyto genetic analysis of the largest case series of 10 patients and found markers specific for synoviocytes and did not find any markers for macrophages. They concluded that malignant cells are derived from the clusterin-positive large mononuclear cells which represent synoviocytes [7].

**Figure 1:** MRI (a) axial T1 WI nonfat saturated demonstrates mild hyperintensity compared to skeletal muscles. (b) Axial T2 WI with fat saturation demonstrates marked homogenous hyperintensity. (c) Axial subtraction image (pre- and post-IV gadolinium contrast) T1 WI with fat saturation confirms the homogeneous avid enhancement. (d) Axial T1 WI with fat saturation, precontrast demonstrates mild hypointensity compared to skeletal muscles. No fat signal suppression. (e) Coronal T1 WI with fat saturation, post-IV gadolinium contrast injection demonstrates homogeneous avid enhancement.
We reviewed clinical and radiological features in a total of 57 cases of malignant tenosynovial giant cell tumor, summarized in Table 1. We found almost equal gender distribution with a slight female predominance (55%). It was found to affect older adults with a median age of 51 years. On rare occasions, it was found in young adults, and only one investigator reported a case in a 12-year-old child with a primary thigh malignant TS-GCT [6]. They were mostly found in the extra-articular soft tissue and with an average size of 9.8 cm found. They tend to present in the lower limb (63%), favoring the soft tissue around the knee, followed by the upper limbs, then axial skeleton. It is notable that both primary and secondary subtypes occurred equally. Secondary malignant recurrence was variable; it occurred either as early as few months or many years following a disease-free period. Kalil and Unni reported secondary malignant transformation 64 years after the initial diagnosis of an ankle TSGCT [8].

Our case showed atypical clinical presentation including younger age of presentation, smaller size, and unusual location. Interestingly, it was found in a subcutaneous location of the mid thigh far away from the joint and away from any synovial structure. Such location is strange since it is believed to be synoviocytic in origin [7]. One author reported similar unusual subcutaneous location of malignant TS-GCT one in the gluteal region and another in the upper thigh [24]. Another showed similar subcutaneous location of benign TS-GCT [20]. Our case also showed a considerable smaller tumor size. This feature was also shared with other two reported cases of subcutaneous malignant TS-GCT. This might be due to their superficial location which led to earlier discovery.

MRI features of malignant TS-GCT varied. No specific radiological characteristics were found to differentiate it from other soft tissue sarcoma. Most authors reported malignant TS-GCT as ill-defined heterogenous lobulated lesion. Some

Figure 2: The tumor grossly shows fleshy gray cut surface with well-circumscribed round edges (a). Histological examination shows nested pseudoalveolar proliferation of histiocytes and synoviocytes showing abundant eosinophilic cytoplasm with some perinuclear hemosiderin (H&E, (b) -100x and (c) -200x). Scattered multinucleated osteoclast-like giant cells are seen (H&E (c) -200x, arrow). The tumor shows atypical cytological features in the form of atypical mitotic figures (H&E (d) -400x, arrow). The neoplastic cells are diffusely positive for immunohistochemical stain for clusterin antibody (clusterin IHC, (e) -upper right insert).
Table 1: Summary of previous reported cases of malignant TS-GCT.

| Study | No. | Sex | Age  | Location | Type | Size | Type        | Recurrence | Metastases | Follow-up |
|-------|-----|-----|------|----------|------|------|-------------|------------|------------|-----------|
| Castens and Howell [3] | 1 | F | 48 | Foot | E | NA | Metachronous (6 y) | Yes | Thigh, groin (10 y) | AWD (9 y) |
| Schajowicz [9] | 1 | NA | NA | Knee | NA | NA | Metachronous (NA) | No | Lung (2 y) | DOD (2 y) |
| Ushijima et al. [10] | 1 | M | 59 | Knee | I | 12 | Metachronous (10 y) | Yes | Thigh, LN, back, ribs (2 y) | AWD (6 y) |
| Nielsen and Kiaer [11] | 1 | M | 67 | Knee | I | 12 | De novo | Yes | Pelvic, sacrum, spine, lung, pleura, thyroid (4 m) | DOD (8 m) |
| Abdul-Karim et al. [2] | 1 | F | 43 | Knee | E | 17 | Metachronous (11 y) | No | No | NED (5 y) |
| Shinjo et al. [12] | 1 | M | 59 | Knee | E | 20 | De novo | NA | No | NED (13 y) |
| | | M | 57 | Foot | E | 6 | De novo | Yes | Groin (11 m) | DOD (21 m) |
| | | F | 37 | Knee | NA | NA | Metachronous (10 m) | Yes | No | NED (NA) |
| | | F | 74 | Knee | NA | NA | De novo | Yes | LN (NA) | DOD (41 m) |
| | | F | 71 | TMJ | NA | NA | Metachronous (NA) | Yes | Lung (NA) | DOD (NA) |
| | | M | 12 | Thigh | E | NA | De novo | No | Spine, lung (5 y) | DOD (5 y) |
| | | F | 79 | Ankle | E | NA | Metachronous (NA) | No | No | DOD (NA) |
| | | F | 38 | Ankle | I | NA | De novo | No | No | NED (3 y) |
| Bertoni et al. [6] | 8 | M | 59 | Knee | E | 20 | De novo | NA | No | NED (13 m) |
| | | M | 57 | Foot | E | 6 | De novo | Yes | Groin (11 m) | DOD (21 m) |
| | | F | 37 | Knee | NA | NA | Metachronous (10 m) | Yes | No | NED (NA) |
| | | F | 74 | Knee | NA | NA | De novo | Yes | LN (NA) | DOD (41 m) |
| | | F | 71 | TMJ | NA | NA | Metachronous (NA) | Yes | Lung (NA) | DOD (NA) |
| | | M | 12 | Thigh | E | NA | De novo | No | Spine, lung (5 y) | DOD (5 y) |
| | | F | 79 | Ankle | E | NA | Metachronous (NA) | No | No | DOD (NA) |
| | | F | 38 | Ankle | I | NA | De novo | No | No | NED (3 y) |
| Kalil and Unni [8] | 1 | F | 85 | Ankle | I | NA | Metachronous (58 y) | Yes | Lung, LN (NA) | DOD (1 y) |
| Layfield et al. [13] | 2 | M | 42 | Hand | E | 4.5 | De novo | NA | No | NED (13 m) |
| | | F | 21 | Thigh | E | 3 | De novo | Yes | No | NED (NA) |
| | | F | 50 | Paravertebral | E | 13 | De novo | Yes | Lung (21 m) | DOD (35 m) |
| | | F | 58 | Elbow | E | 3 | De novo | Yes | No | NED (6 m) |
| | | F | 33 | Sacrococcygeal | E | 2.5 | De novo | NA | No | NED (6 m) |
| | | F | 26 | Knee | E | 13 | De novo | NA | No | NED (NA) |
| Somerhause and Dal Cin [1] | 1 | M | 65 | Forearm | E | 1.5 | De novo | NA | No | NED (2 y) |
| | | M | 45 | Ankle | I | NA | Metachronous (8 m) | No | No | NED (6 m) |
| | | F | 53 | Finger | E | NA | De novo | Yes | No | NED (8 m) |
| Wu et al. [14] | 1 | M | 37 | Sacrum | E | 5 | Metachronous (10 m) | Yes | LN (7 m) | AWD (NA) |
| | | M | 45 | Ankle | I | 8 | Metachronous (7 m) | No | Spine (9 m) | DOD (NA) |
| | | F | 78 | Knee | E | 8 | De novo | Yes | No | NED (NA) |
| | | F | 39 | Forearm | E | 12 | Metachronous (31 y) | No | LN, lung (11 m) | AWD (NA) |
| | | M | 52 | Knee | E | 10 | De novo | No | No | NED (NA) |
| Study                        | No. | Sex | Age | Location | Type   | Size | Type       | Recurrence | Metastases          | Follow-up   |
|------------------------------|-----|-----|-----|----------|--------|------|------------|-------------|---------------------|-------------|
| Yoon et al. [18]             | 1   | M   | 29  | TMJ      | E      | 7    | Metachronous (6 y) | No          | Lung (30 m)         | AWD (30 m)  |
| Imakiire et al. [19]         | 1   | F   | 56  | Knee     | I      | NA   | Metachronous (11 y) | Yes         | Vertebra, pelvis (20 m) | AWD (21 m)  |
| Kondo et al. [20]            | 1   | F   | 58  | Buttock  | E      | 6    | De novo    | No          | Lung (6 m)          | AWD (13 m)  |
| Theunissen et al. [21]       | 1   | M   | 66  | Wrist    | E      | 6    | Metachronous (2 y) | Yes         | No (2 y)            | NED (2 y)   |
| Richman et al. [22]          | 1   | F   | 55  | Leg      | E      | 20   | Metachronous (7 w) | No          | Lung, LN (NA)       | DOD (21 m)  |
| Alexiev et al. [23]          | 1   | M   | 57  | Knee     | I      | 4.6  | Metachronous (NA) | No          | Lung (2 y)          | NA          |

Al-Ibraheemi et al. [7]  

| Study                        | No. | Sex | Age | Location | Type   | Size | Type       | Recurrence | Metastases          | Follow-up   |
|------------------------------|-----|-----|-----|----------|--------|------|------------|-------------|---------------------|-------------|
| M 32                         | Thigh | NA | NA  | De novo  | No     |      |            |             | Lung (NA)          | AWD (6 m)   |
| M 61                         | Finger | NA | NA  | De novo  | No     |      |            |             | No                  | NED (15 m)  |
| M 60                         | Ankle  | NA | NA  | Metachronous (NA) | No | Lung, LN (NA)          | DOD (6 m)   |
| F 56                         | Leg    | NA | NA  | De novo  | No     |      |            |             | No                  | NED (7 m)   |
| F 72                         | Thumb  | NA | NA  | De novo  | No     |      |            |             | No                  | NED (5 m)   |
| M 72                         | Pelvic | NA | NA  | De novo  | No     |      |            |             | No                  | DOD (1 m)   |
| F 26                         | Toe    | NA | NA  | De novo  | No     |      |            |             | No                  | NED (27 m)  |
| M 64                         | Pelvic | NA | NA  | Metachronous (NA) | No | Lung (NA)          | DOD (66 m)  |
| M 27                         | Pelvic | NA | NA  | De novo  | Yes    |      |            |             | No                  | AWD (48 m)  |
| M 46                         | Wrist  | NA | NA  | De novo  | Recent |      |            |             | No                  | Recent      |

Nakayama et al. [4]  

| Study                        | No. | Sex | Age | Location | Type   | Size | Type       | Recurrence | Metastases          | Follow-up   |
|------------------------------|-----|-----|-----|----------|--------|------|------------|-------------|---------------------|-------------|
| F 33                         | Knee  | I   | NA  | Metachronous (21 y) | Yes | LN, lung (8 m)          | DOD (6 y)   |
| M 53                         | Thigh | E   | NA  | De novo  | Yes    | LN, lung (1 y)         | DOD (20 m)  |
| F 55                         | Knee  | E   | NA  | Metachronous (3 m) | Yes | LN, lung (2 m)         | DOD (23 m)  |
| F 46                         | Hip   | E   | 10  | De novo  | Yes    | Lung (initial)        | DOD (9 m)   |
| M 44                         | Thigh | E   | NA  | Metachronous (3 y) | Yes | Lung (initial)        | DOD (17 m)  |
| M 55                         | Knee  | E   | NA  | Metachronous (3 m) | No   | LN, lung (1 y)         | DOD (2 y)   |

Salem et al.                  

| Study                        | No. | Sex | Age | Location | Type   | Size | Type       | Recurrence | Metastases          | Follow-up   |
|------------------------------|-----|-----|-----|----------|--------|------|------------|-------------|---------------------|-------------|
| M 68                         | Elbow | E   | 6   | De novo  | No     |      |            |             | No                  | AWD (NA)    |
| F 67                         | Leg   | E   | 17  | De novo  | No     |      |            |             | No                  | NED (NA)    |
| F 46                         | Thigh | E   | 5   | De novo  | No     |      |            |             | LN (9 m)           | NED (NA)    |

M: male; F: female; NA: not available; E: extra-articular; I: intra-articular; LN: lymph nodes; NED: no evidence of disease; AWD: alive with disease; DOD: death of disease.
found MRI features of classical TS-GCT including presence of dark nodules in both T1 and T2 indicating hemosiderin deposits, multiple lobulation, and periarticular position. Presence of such features may serve as a clue. Areas of necrosis and cystic changes have been also described. Some reported involvement of the underlying bone [17]. Surprisingly, our case showed well defined homogenous enhancement lesion with no lobulation or dark nodules. It was found in the subcutaneous tissue separated from the underlying fascia by a clear fat plane. Such MRI features are uncommon for this tumor.

Initial biopsy showed classical TS-GCT features that might be due to sampling from the benign component. After resection, further analysis showed features of malignant TS-GCT including nested pseudoalveolar proliferation of histiocytes and synoviocytes showing abundant eosinophilic cytoplasm with some perinuclear hemosiderin. Scattered multinucleated osteoclast-like giant cells are seen. The tumor shows atypical cytological features in the form of atypical mitotic figures. The neoplastic cells are diffusely positive for immunohistochemical stain for clusterin antibody.

Malignant TS-GCT was shown to be overly aggressive with high rate of local recurrence and distal metastases. Nearly half of the cases occurred after surgical resection. Some had multiple recurrence and required multiple surgeries. Metastases was also common, with the lung being the most common site in 45% of the cases followed by the regional lymph nodes in 24% of the cases. It also showed tendency to metastasize to other distant and unusual location including spine, pleura, bladder, ilium, mesentry, and thyroid. The unusual preferen of spread to the regional lymph node and distal soft tissue sites is another unique feature of this tumor. Prognosis becomes extremely unfavorable with a high mortality rate of 67% once metastases have been discovered.

Surgery is the mainstay of treatment for malignant tenosynovial giant cell tumor [15]. Most investigators treated this disease aggressively radical resection including surgical amputation. Some added additional adjuvant chemotherapy and or radiation therapy. Hence, the discovery of aberrant CSF1 expression and the expression of other markers such as RANK use of other systemic treatment including denosumab and tyrosin kinase inhibitors with CSF1R inhibitory activity were considered [4, 7, 25]. Due to the small number of cases and the inconsistency of treatment modalities, the efficacy of adjuvant treatment is hard to assess, but did not seem to change the course of the disease. Unfortunately, most cases showed disease progression regardless of mode of treatment with a high tendency for local recurrence and metastasis [4, 15].

4. Conclusion

Malignant TS-GCT are extremely rare and difficult to diagnose. Our case showed atypical clinical and radiological features. She was younger than the average, the tumor size was smaller, and the tumor was present in an unusual location in the subcutaneous tissue away from any synovial tissue. In cases with high level of suspension, it is recommended to proceed with biopsy prior to definitive management. The mainstay of treatment in such disease is local surgical control. Other treatment modalities are still under investigation, but so far, it was not able to change the disease course. Due to the aggressive nature of disease and high risk of recurrence and metastases, close follow up is advised.

Abbreviations

TS-GCT: Tenosynovial giant cell tumor.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] N. S. Somerhausen and P. Dal Cin, "Diffuse-type giant cell tumor," in World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, C. D. M. Fletcher, K. K. Unni, and M. Mertens, Eds., pp. 112–114, IARC Press, Lyon, 2002.

[2] F. W. Abdul-Karim, A. K. El-Naggar, M. J. Joyce, J. T. Makley, and J. R. Carter, "Diffuse and localized tenosynovial giant cell tumor and pigmented villonodular synovitis: a clinicopathologic and flow cytometric DNA analysis," Human Pathology, vol. 23, no. 7, pp. 729–735, 1992.

[3] P. H. B. Castens and R. S. Howell, "Malignant giant cell tumor of tendon sheath," Virchows Archiv. A, Pathological Anatomy and Histology, vol. 382, no. 2, pp. 237–243, 1979.

[4] R. Nakayama, J. P. Jagannathan, N. Ramaiya et al., "Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy," BMC Cancer, vol. 18, no. 1, p. 1296, 2018.

[5] F. M. Enzinger and S. W. Weiss, Soft Tissue Tumors, CV Mosby, Philadelphia, 3rd ed. edition, 1995.

[6] F. Bertoni, K. K. Unni, J. W. Beabout, and F. H. Sim, "Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis)," The American Journal of Surgical Pathology, vol. 21, no. 2, pp. 153–163, 1997.

[7] A. Al-Ibraheemi, W. A. Ahrens, K. Fritchie et al., "Malignant tenosynovial giant cell tumor: the true "synovial sarcoma"? A clinicopathologic, immunohistochemical, and molecular cytogenetic study of 10 cases, supporting origin from synoviocytes," Modern Pathology, vol. 32, no. 2, pp. 242–251, 2019.

[8] R. K. Kalil and K. K. Unni, "Malignancy in pigmented villonodular synovitis," Skeletal Radiology, vol. 27, no. 7, pp. 392–395, 1998.

[9] F. Schajowicz, Tumors and Tumor-Like Lesions of Bone and Joints, Springer-Verlag, New York, 1981.

[10] M. Ushijima, H. Hashimoto, M. Tsukiyoshi, M. Enjoji, Y. Miyamoto, and A. Okue, "Malignant giant cell tumor of tendon sheath report of a case," Pathology International, vol. 35, no. 3, pp. 699–709, 1985.

[11] A. L. Nielsen and T. Kjaer, "Malignant giant cell tumor of synovium and locally destructive pigmented villonodular synovitis: ultrastructural and immunohistochemical study and review of the literature," Human Pathology, vol. 20, no. 8, pp. 765–771, 1989.

[12] K. Shinjo, N. Miyake, and Y. Takahashi, "Malignant giant cell tumor of the tendon sheath: an autopsy report and review of the literature," Japanese Journal of Clinical Oncology, vol. 23, no. 5, pp. 317–324, 1993.
[13] L. J. Layfield, A. Meloni-Ehrig, K. Liu, R. Shepard, and J. M. Harrelson, "Malignant giant cell tumor of synovium (malignant pigmented villonodular synovitis)," *Archives of Pathology & Laboratory Medicine*, vol. 124, no. 11, pp. 1636–1641, 2000.

[14] N. L. Wu, P. F. Hsiao, B. F. Chen, H. C. Chen, and H. Y. Su, "Malignant giant cell tumor of the tendon sheath," *International Journal of Dermatology*, vol. 43, no. 1, pp. 54–57, 2004.

[15] A. K. Bhadra, R. Pollock, R. P. Tirabosco et al., "Primary tumours of the synovium. A report of four cases of malignant tumour," *The Journal of Bone and Joint Surgery. British Volume*, vol. 89, no. 11, pp. 1504–1508, 2007.

[16] Y. Oda, T. Takahira, R. Yokoyama, and M. Tsuneyoshi, "Diffuse-type giant cell tumor/pigmented villonodular synovitis arising in the sacrum: malignant form," *Pathology International*, vol. 57, no. 9, pp. 627–631, 2007.

[17] C. F. Li, J. W. Wang, W. W. Huang et al., "Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature," *The American Journal of Surgical Pathology*, vol. 32, no. 4, pp. 587–599, 2008.

[18] H. J. Yoon, Y. A. Cho, J. I. Lee, S. P. Hong, and S. D. Hong, "Malignant pigmented villonodular synovitis of the temporomandibular joint with lung metastasis: a case report and review of the literature," *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics*, vol. 111, no. 5, pp. e30–e36, 2011.

[19] N. Imakiire, T. Fujino, T. Morii et al., "Malignant pigmented villonodular synovitis in the knee - report of a case with rapid clinical progression," *The Open Orthopaedics Journal*, vol. 5, pp. 13–16, 2011.

[20] R. Kondo, J. Akiba, K. Hiraoka et al., "Malignant diffuse-type tenosynovial giant cell tumor of the buttock," *Pathology International*, vol. 62, no. 8, pp. 559–564, 2012.

[21] C. I. Theunissen, J. Bras, K. P. Lienden, and M. C. Obdeijn, "Malignant giant cell tumor in the carpal tunnel: a case report and review of literature," *Journal of Wrist Surgery*, vol. 2, no. 3, pp. 271–275, 2013.

[22] D. M. Richman, S. C. Bresler, M. H. Rosenthal, and S. A. Howard, "Malignant tenosynovial giant cell tumor of the leg: a radiologic-pathologic correlation and review of the literature," *Journal of Clinical Imaging Science*, vol. 5, p. 13, 2015.

[23] B. A. Alexiev, Y. Tumer, and G. Y. Yang, "Malignant tenosynovial giant cell tumor with CDKN2A/B genomic alteration: a histological, immunohistochemical, and molecular study," *Human Pathology*, vol. 63, pp. 144–148, 2017.

[24] D. A. Sanghvi, N. C. Purandare, N. A. Jambhekar, M. G. Agarwal, and A. Agarwal, "Diffuse-type giant cell tumor of the subcutaneous thigh," *Skeletal Radiology*, vol. 36, no. 4, pp. 327–330, 2007.

[25] W. D. Tap, Z. A. Wainberg, S. P. Anthony et al., "Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor," *The New England Journal of Medicine*, vol. 373, no. 5, pp. 428–437, 2015.